Skip to content
2000
Volume 25, Issue 18
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Background

Certain types of non-Hodgkin lymphoma, such as Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL), often necessitate multiple treatment approaches. One promising avenue is immune checkpoint inhibition, specifically targeting the programmed cell death protein 1 (PD-1). Pembrolizumab, an immunotherapy medication, acts by inhibiting the PD-1 pathway and has gained approval from the United States Food and Drug Administration (FDA) for treating various cancers, including melanoma, Hodgkin lymphoma, lung cancer, and endometrial cancer. This meta-analysis aims to assess the impact of pembrolizumab on patient outcomes and survival in the context of B-cell lymphoma.

Methods

This study adhered to The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Two independent reviewers conducted a thorough search of electronic databases up to September 28, 2023. We included studies that investigated the effects of pembrolizumab treatment on patient outcomes and survival in individuals diagnosed with B-cell lymphoma. All statistical analysis was performed by STATA V.17.

Results

Our meta-analysis encompassed 13 eligible clinical trials involving 426 B-cell lymphoma patients. The study findings revealed a Disease Control Rate (DCR) of 63%, Overall Response Rate (ORR) of 42%, Complete Response Rate (CRR) of 23%, and 1-year Overall Survival Rate (OSR) of 64%. Notably, 65% of patients experienced Treatment-Related Adverse Events (TRAEs) of any grade, with 39% encountering grade ≥ 3 TRAEs. The most prevalent grade ≥ 3 TRAEs included anemia, neutropenia, thrombocytopenia, and lymphopenia.

Conclusion

The utilization of pembrolizumab, both as a monotherapy and in combination with other drugs, presented encouraging outcomes in patients with B-cell lymphoma.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206347612250314043307
2025-03-26
2025-09-14

  • From This Site

    /content/journals/acamc/10.2174/0118715206347612250314043307
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ArmitageJ.O. WeisenburgerD.D. New approach to classifying non-Hodgkin’s lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin’s lymphoma classification project.J. Clin. Oncol.19981682780279510.1200/JCO.1998.16.8.2780 9704731
     [Google Scholar]
  2. TerasL.R. DeSantisC.E. CerhanJ.R. MortonL.M. JemalA. FlowersC.R. 2016 US lymphoid malignancy statistics by World Health Organization subtypes.CA Cancer J. Clin.201666644345910.3322/caac.21357 27618563
     [Google Scholar]
  3. CrumpM. NeelapuS.S. FarooqU. Van Den NesteE. KuruvillaJ. WestinJ. LinkB.K. HayA. CerhanJ.R. ZhuL. BoussettaS. FengL. MaurerM.J. NavaleL. WiezorekJ. GoW.Y. GisselbrechtC. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study.Blood2017130161800180810.1182/blood‑2017‑03‑769620 28774879
     [Google Scholar]
  4. WangY. FarooqU. LinkB.K. LarsonM.C. KingR.L. MaurerM.J. AllmerC. HefaziM. ThompsonC.A. MicallefI.N. JohnstonP.B. HabermannT.M. WitzigT.E. AnsellS.M. CerhanJ.R. NowakowskiG.S. Late relapses in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.J. Clin. Oncol.201937211819182710.1200/JCO.19.00014 31170029
     [Google Scholar]
  5. ReddyN.M. ThieblemontC. Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: Current perspective.Ann. Oncol.201728112680269010.1093/annonc/mdx358 29045503
     [Google Scholar]
  6. RuppertA.S. DixonJ.G. SallesG. WallA. CunninghamD. PoeschelV. HaiounC. TillyH. GhesquieresH. ZiepertM. FlamentJ. FlowersC. ShiQ. SchmitzN. International prognostic indices in diffuse large B-cell lymphoma: A comparison of IPI, R-IPI, and NCCN-IPI.Blood2020135232041204810.1182/blood.2019002729 32232482
     [Google Scholar]
  7. CasuloC. ByrtekM. DawsonK.L. ZhouX. FarberC.M. FlowersC.R. HainsworthJ.D. MaurerM.J. CerhanJ.R. LinkB.K. ZelenetzA.D. FriedbergJ.W. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare study.J. Clin. Oncol.201533232516252210.1200/JCO.2014.59.7534 26124482
     [Google Scholar]
  8. SallesG. SeymourJ.F. OffnerF. López-GuillermoA. BeladaD. XerriL. FeugierP. BouabdallahR. CatalanoJ.V. BriceP. CaballeroD. HaiounC. PedersenL.M. DelmerA. SimpsonD. LeppaS. SoubeyranP. HagenbeekA. CasasnovasO. IntragumtornchaiT. FerméC. da SilvaM.G. SebbanC. ListerA. EstellJ.A. MiloneG. SonetA. MendilaM. CoiffierB. TillyH. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial.Lancet20113779759425110.1016/S0140‑6736(10)62175‑7 21176949
     [Google Scholar]
  9. WeberJ. Immune checkpoint proteins: A new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade.Semin. Oncol.2010375430
     [Google Scholar]
  10. KyiC. PostowM.A. Checkpoint blocking antibodies in cancer immunotherapy.FEBS Lett.2014588236837610.1016/j.febslet.2013.10.015 24161671
     [Google Scholar]
  11. Sanchez-LockhartM. RojasA.V. FettisM.M. BausermanR. HigaT.R. MiaoH. WaughR.E. MillerJ. T cell receptor signaling can directly enhance the avidity of CD28 ligand binding.PLoS One201492e8926310.1371/journal.pone.0089263 24586641
     [Google Scholar]
  12. ArmandP. RodigS. MelnichenkoV. ThieblemontC. BouabdallahK. TumyanG. ÖzcanM. PortinoS. FogliattoL. CaballeroM.D. WalewskiJ. GulbasZ. RibragV. ChristianB. PeriniG.F. SallesG. SvobodaJ. ZainJ. PatelS. ChenP.H. LigonA.H. OuyangJ. NeubergD. ReddR. ChatterjeeA. BalakumaranA. OrlowskiR. ShippM. ZinzaniP.L. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma.J. Clin. Oncol.201937343291329910.1200/JCO.19.01389 31609651
     [Google Scholar]
  13. ZinzaniP.L. RibragV. MoskowitzC.H. MichotJ.M. KuruvillaJ. BalakumaranA. ZhangY. ChlostaS. ShippM.A. ArmandP. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.Blood2017130326727010.1182/blood‑2016‑12‑758383 28490569
     [Google Scholar]
  14. El-ghazziN. DurandoX. GiroA. HerrmannT. Targeted treatment of advanced endometrial cancer: Focus on Pembrolizumab.OncoTargets Ther.20231635936910.2147/OTT.S368050 37288137
     [Google Scholar]
  15. NovelloS. KowalskiD.M. LuftA. GümüşM. VicenteD. MazièresJ. Rodríguez-CidJ. TafreshiA. ChengY. LeeK.H. GolfA. SugawaraS. RobinsonA.G. HalmosB. JensenE. SchwarzenbergerP. PietanzaM.C. Paz-AresL. Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study.J. Clin. Oncol.202341111999200610.1200/JCO.22.01990 36735893
     [Google Scholar]
  16. WookeyV. GrotheyA. Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer.Therap. Adv. Gastroenterol.2021141756284821102446010.1177/17562848211024460 34262612
     [Google Scholar]
  17. ZinzaniP.L. ThieblemontC. MelnichenkoV. BouabdallahK. WalewskiJ. MajlisA. FogliattoL.M. Martin Garcia-SanchoA. ChristianB. GulbasZ. ÖzcanM. PeriniG.F. GhesquieresH. ShippM.A. ThompsonS. ChakrabortyS. MarinelloP. ArmandP. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: Final analysis of KEYNOTE-170. Blood,20231422blood.202201934010.1182/blood.2022019340 37130017
     [Google Scholar]
  18. Pai-ScherfL. BlumenthalG.M. LiH. SubramaniamS. Mishra-KalyaniP.S. HeK. ZhaoH. YuJ. PacigaM. GoldbergK.B. McKeeA.E. KeeganP. PazdurR. FDA approval summary: Pembrolizumab for treatment of metastatic non‐small cell lung cancer: First‐line therapy and beyond.Oncologist201722111392139910.1634/theoncologist.2017‑0078 28835513
     [Google Scholar]
  19. HazarikaM. ChukM.K. TheoretM.R. MushtiS. HeK. WeisS.L. PutmanA.H. HelmsW.S. CaoX. LiH. ZhaoH. ZhaoL. WelchJ. GrahamL. LibegM. SridharaR. KeeganP. PazdurR.U.S. FDA approval summary: Nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab.Clin. Cancer Res.201723143484348810.1158/1078‑0432.CCR‑16‑0712 28087644
     [Google Scholar]
  20. KazandjianD. SuzmanD.L. BlumenthalG. MushtiS. HeK. LibegM. KeeganP. PazdurR. FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy.Oncologist201621563464210.1634/theoncologist.2015‑0507 26984449
     [Google Scholar]
  21. PageM.J. McKenzieJ.E. BossuytP.M. BoutronI. HoffmannT.C. MulrowC.D. ShamseerL. TetzlaffJ.M. AklE.A. BrennanS.E. ChouR. GlanvilleJ. GrimshawJ.M. HróbjartssonA. LaluM.M. LiT. LoderE.W. Mayo-WilsonE. McDonaldS. McGuinnessL.A. StewartL.A. ThomasJ. TriccoA.C. WelchV.A. WhitingP. MoherD. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.Int. J. Surg.20218810590610.1016/j.ijsu.2021.105906 33789826
     [Google Scholar]
  22. DeeksJ.J. HigginsJ.P.T. AltmanD.G. Analysing data and undertaking meta-analyses.In: Cochrane Handbook for Systematic Reviews of Interventions.WILEY201924128410.1002/9781119536604.ch10
     [Google Scholar]
  23. WitzigT.E. MaddocksK.J. SharmanJ.P. EdenfieldW.J. VoseJ. Di SimoneC. VoseJ. YimerH.A. Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).J. Clin. Oncol.2019371510.1200/JCO.2019.37.15_suppl.7519
     [Google Scholar]
  24. FrigaultM.J. ArmandP. ReddR.A. JeterE. MerrymanR.W. ColemanK.C. HerreraA.F. DahiP. NietoY. LaCasceA.S. FisherD.C. NgS.Y. OdejideO.O. FreedmanA.S. KimA.I. CrombieJ.L. JacobsonC.A. JacobsenE.D. WongJ.L. BsatJ. PatelS.S. RitzJ. RodigS.J. ShippM.A. ChenY.B. JoyceR.M. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation.Blood Adv.20204112212610.1182/bloodadvances.2019000784 31917843
     [Google Scholar]
  25. SmithS.D. TillB.G. ShadmanM.S. LynchR.C. CowanA.J. WuQ.V. VoutsinasJ. RasmussenH.A. BlueK. UjjaniC.S. ShustovA. CassadayR.D. FrommJ.R. GopalA.K. Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: Potential for biomarker driven therapy.Br. J. Haematol.202018961119112610.1111/bjh.16494 32030732
     [Google Scholar]
  26. ChongE.A. AlanioC. SvobodaJ. NastaS.D. LandsburgD.J. LaceyS.F. RuellaM. BhattacharyyaS. WherryE.J. SchusterS.J. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.Blood202213971026103810.1182/blood.2021012634 34496014
     [Google Scholar]
  27. GregoryG.P. KumarS. WangD. MahadevanD. WalkerP. Wagner-JohnstonN. EscobarC. BannerjiR. BhutaniD. ChangJ. Hernandez-IlizaliturriF.J. KleinA. PagelJ.M. RybkaW. YeeA.J. MohrbacherA. HuangM. FarooquiM. MarinelloP. QuachH. Pembrolizumab plus dinaciclib in patients with hematologic malignancies: The phase 1b KEYNOTE-155 study.Blood Adv.2022641232124210.1182/bloodadvances.2021005872 34972202
     [Google Scholar]
  28. PinnixC.C. DabajaB.S. GuntherJ.R. FangP. WuS. AhmedS. SteinerR.E. NairR. StratiP. WestinJ. FayadL. IyerS.P. RodriguezM.A. LeeH.J. SamaniegoF. ChiharaD. JainP. FengL. FlowersC.R. NeelapuS.S. NastoupilL.J. Phase II study of Pembrolizumab and fractionated external beam radiotherapy in patients with relapsed and refractory large B-cell lymphoma.Blood2022140Suppl. 13741374310.1182/blood‑2022‑168540
     [Google Scholar]
  29. GodfreyJ. MeiM. ChenL. SongJ.Y. BedellV. BuddeE. ArmenianS. PuverelS. NikolaenkoL. ChenR. DanielsS. KennedyN. PetersL. RosenS.T. FormanS.J. PopplewellL.L. KwakL.W. HerreraA.F. Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.Haematologica2023109253354210.3324/haematol.2023.283002 37470137
     [Google Scholar]
  30. KuruvillaJ. ArmandP. HamadaniM. KlineJ. MoskowitzC.H. AviganD. BrodyJ.D. RibragV. HerreraA.F. MorschhauserF. KanateA. ZinzaniP.L. BitranJ. GhesquieresH. SchusterS.J. FarooquiM. MarinelloP. BartlettN.L. Pembrolizumab for patients with non-Hodgkin lymphoma: Phase 1b KEYNOTE-013 study.Leuk. Lymphoma202364113013910.1080/10428194.2022.2136956 36398795
     [Google Scholar]
  31. JaegerU. WorelN. McGuirkJ.P. RiedellP.A. FleuryI. DuY. HanX. PearsonD. RedondoS. WallerE.K. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: Phase 1b PORTIA study results.Blood Adv.20237112283228610.1182/bloodadvances.2022007779 36044388
     [Google Scholar]
  32. AmitaiI. RoosK. RashediI. JiangY. MangoffK. KleinG. ForwardN. StewartD. LaneuvilleP. Bence-BrucklerI. MangelJ. TomlinsonG. BerinsteinN.L. PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL.Eur. J. Haematol.2023111219120010.1111/ejh.13982 37157906
     [Google Scholar]
  33. SherA.F. GolshaniG.M. WuS. Fatal adverse events associated with pembrolizumab in cancer patients: A meta-analysis.Cancer Invest.202038213013810.1080/07357907.2020.1721521 31985314
     [Google Scholar]
  34. NarayananV. KoshyC. Fatigue in cancer: A review of literature.Indian J. Palliat. Care2009151192510.4103/0973‑1075.53507 20606851
     [Google Scholar]
  35. BowerJ.E. Cancer-related fatigue—mechanisms, risk factors, and treatments.Nat. Rev. Clin. Oncol.2014111059760910.1038/nrclinonc.2014.127 25113839
     [Google Scholar]
  36. TanQ. LiuL. HuangY. DongX. ChenL. Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review.Front. Oncol.20221297342110.3389/fonc.2022.973421 36505877
     [Google Scholar]
  37. BurnsE.A. GeeK. KieserR.B. XuJ. ZhangY. CrenshawA. MuhsenI.N. MylavarapuC. EsmailA. ShahS. UmoruG. SunK. GuerreroC. GongZ. HeyneK. SinghM. ZhangJ. BernickerE.H. AbdelrahimM. Impact of infections in patients receiving pembrolizumab-based therapies for non-small cell lung cancer.Cancers20221518110.3390/cancers15010081 36612078
     [Google Scholar]
  38. YasmeenT. AliJ. KhanK. SiddiquiN. Frequency and causes of anemia in Lymphoma patients.Pak. J. Med. Sci.2019351616510.12669/pjms.35.1.91 30881397
     [Google Scholar]
  39. MorrowT.J. VolpeS. GuptaS. TannousR. FridmanM. Anemia of cancer in intermediate-grade non-Hodgkin’s lymphoma.South. Med. J.200295888989610.1097/00007611‑200295080‑00021 12190227
     [Google Scholar]
  40. SpivakJ.L. Iron and the anemia of chronic disease.Oncology (Williston Park)2002169Suppl. 102533 12380952
     [Google Scholar]
  41. KanyS. VollrathJ.T. ReljaB. Cytokines in inflammatory disease.Int. J. Mol. Sci.20192023600810.3390/ijms20236008 31795299
     [Google Scholar]
  42. SohrabS.S. RajR. NagarA. HawthorneS. Paiva-SantosA.C. KamalM.A. El-DalyM.M. AzharE.I. SharmaA. Chronic inflammation’s transformation to cancer: A nanotherapeutic paradigm.Molecules20232811441310.3390/molecules28114413 37298889
     [Google Scholar]
  43. BirgegårdG. AaproM.S. BokemeyerC. DicatoM. DringsP. HornedoJ. KrzakowskiM. LudwigH. PecorelliS. SchmollH.J. SchneiderM. SchrijversD. ShashaD. van BiesenS. Cancer-related anemia: Pathogenesis, prevalence and treatment.Oncology200568Suppl. 131110.1159/000083128 15855811
     [Google Scholar]
  44. ArmandP. ZinzaniP.L. LeeH.J. JohnsonN.A. BriceP. RadfordJ. RibragV. MolinD. VassilakopoulosT.P. TomitaA. von TresckowB. ShippM.A. HerreraA.F. LinJ. KimE. ChakrabortyS. MarinelloP. MoskowitzC.H. Five-year follow-up of KEYNOTE-087: Pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.Blood20231421087888610.1182/blood.2022019386 37319435
     [Google Scholar]
  45. KwokG. YauT.C.C. ChiuJ.W. TseE. KwongY.L. Pembrolizumab (Keytruda).Hum. Vaccin. Immunother.201612112777278910.1080/21645515.2016.1199310 27398650
     [Google Scholar]
  46. ArmandP. ShippM.A. RibragV. MichotJ.M. ZinzaniP.L. KuruvillaJ. SnyderE.S. RicartA.D. BalakumaranA. RoseS. MoskowitzC.H. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure.J. Clin. Oncol.201634313733373910.1200/JCO.2016.67.3467 27354476
     [Google Scholar]
  47. ZinzaniP.L. RibragV. MoskowitzC.H. MichotJ-M. KuruvillaJ. BalakumaranA. SnyderE. MarinelloP. ShippM.A. ArmandP. Phase 1b study of PD-1 blockade with pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL).Blood201512623398610.1182/blood.V126.23.3986.3986
     [Google Scholar]
  48. RoemerM.G.M. AdvaniR.H. LigonA.H. NatkunamY. ReddR.A. HomerH. ConnellyC.F. SunH.H. DaadiS.E. FreemanG.J. ArmandP. ChapuyB. de JongD. HoppeR.T. NeubergD.S. RodigS.J. ShippM.A. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome.J. Clin. Oncol.201634232690269710.1200/JCO.2016.66.4482 27069084
     [Google Scholar]
  49. MitaniY. UsamiE. KimuraM. NakaoT. OkadaK. MatsuokaT. KokuryouT. YoshimuraT. YamakawaM. Risk factors for neutropenia with lenalidomide plus dexamethasone therapy for multiple myeloma.Pharmazie2016716349351 27455556
     [Google Scholar]
  50. KurodaY. Infection risks and prevention in patients with multiple myeloma.Rinsho Ketsueki202364910831091 37899186
     [Google Scholar]
  51. ChongE.A. AlanioC. SvobodaJ. NastaS.D. LandsburgD.J. LaceyS.F. RuellaM. BhattacharyyaS. WherryE.J. Phase I/II study of pembrolizumab for progressive diffuse large B cell lymphoma after anti-CD19 directed chimeric antigen receptor modified T cell therapy.Blood20171304121
     [Google Scholar]
  52. ZinzaniP.L. SantoroA. GrittiG. BriceP. BarrP.M. KuruvillaJ. CunninghamD. KlineJ. JohnsonN.A. Mehta-ShahN. LisanoJ. WenR. AkyolA. MoskowitzA.J. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: A 3-year follow-up.Blood Adv.20237185272528010.1182/bloodadvances.2023010254 37352266
     [Google Scholar]
  53. Carlo-StellaC. ZinzaniP.L. SuredaA. AraújoL. CasasnovasO. CarpioC. YehS.P. BouabdallahK. CartronG. KimW.S. CordobaR. KohY. ReA. AlvesD. ChamuleauM. Le GouillS. López-GuillermoA. MoreiraI. van der PoelM.W.M. AbbadessaG. MengR. JiR. LépineL. SaleemR. RibragV. A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.Hematol. Oncol.202341110811910.1002/hon.3089 36251503
     [Google Scholar]
  54. PalombaM.L. CartronG. PopplewellL. RibragV. WestinJ. HuwL.Y. AgarwalS. ShivhareM. HongW.J. RavalA. ChangA.C. PenuelE. MorschhauserF. Combination of Atezolizumab and Tazemetostat in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from a phase Ib study.Clin. Lymphoma Myeloma Leuk.202222750451210.1016/j.clml.2021.12.014 35151584
     [Google Scholar]
  55. KochenderferJ.N. SomervilleR.P.T. LuT. YangJ.C. SherryR.M. FeldmanS.A. McIntyreL. BotA. RossiJ. LamN. RosenbergS.A. Long-duration complete remissions of diffuse large B cell lymphoma after Anti-CD19 chimeric antigen receptor T cell therapy.Mol. Ther.201725102245225310.1016/j.ymthe.2017.07.004 28803861
     [Google Scholar]
  56. CappellK.M. SherryR.M. YangJ.C. GoffS.L. VanasseD.A. McIntyreL. RosenbergS.A. KochenderferJ.N. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy.J. Clin. Oncol.202038323805381510.1200/JCO.20.01467 33021872
     [Google Scholar]
  57. HirayamaA.V. GauthierJ. HayK.A. VoutsinasJ.M. WuQ. PenderB.S. HawkinsR.M. VakilA. SteinmetzR.N. RiddellS.R. MaloneyD.G. TurtleC.J. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.Blood2019134763664010.1182/blood.2019000905 31648294
     [Google Scholar]
  58. NeelapuS.S. LockeF.L. BartlettN.L. LekakisL.J. MiklosD.B. JacobsonC.A. BraunschweigI. OluwoleO.O. SiddiqiT. LinY. TimmermanJ.M. StiffP.J. FriedbergJ.W. FlinnI.W. GoyA. HillB.T. SmithM.R. DeolA. FarooqU. McSweeneyP. MunozJ. AviviI. CastroJ.E. WestinJ.R. ChavezJ.C. GhobadiA. KomanduriK.V. LevyR. JacobsenE.D. WitzigT.E. ReaganP. BotA. RossiJ. NavaleL. JiangY. AycockJ. EliasM. ChangD. WiezorekJ. GoW.Y. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.N. Engl. J. Med.2017377262531254410.1056/NEJMoa1707447 29226797
     [Google Scholar]
  59. ChongE.A. RuellaM. SchusterS.J. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy.N. Engl. J. Med.2021384767367410.1056/NEJMc2030164 33596362
     [Google Scholar]
  60. SchusterS.J. SvobodaJ. ChongE.A. NastaS.D. MatoA.R. AnakÖ. BrogdonJ.L. Pruteanu-MaliniciI. BhojV. LandsburgD. WasikM. LevineB.L. LaceyS.F. MelenhorstJ.J. PorterD.L. JuneC.H. Chimeric antigen receptor T cells in refractory B-Cell lymphomas.N. Engl. J. Med.2017377262545255410.1056/NEJMoa1708566 29226764
     [Google Scholar]
  61. ShahN.N. FryT.J. Mechanisms of resistance to CAR T cell therapy.Nat. Rev. Clin. Oncol.201916637238510.1038/s41571‑019‑0184‑6 30837712
     [Google Scholar]
  62. ChongE.A. MelenhorstJ.J. LaceyS.F. AmbroseD.E. GonzalezV. LevineB.L. JuneC.H. SchusterS.J. PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: Refueling the CAR.Blood201712981039104110.1182/blood‑2016‑09‑738245 28031179
     [Google Scholar]
  63. HillB.T. RobertsZ.J. XueA. RossiJ.M. SmithM.R. Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma.Bone Marrow Transplant.20205561184118710.1038/s41409‑019‑0657‑3 31471571
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206347612250314043307
Loading
Clinical Efficacy and Safety of Pembrolizumab Therapy for B-cell Lymphoma: A Systematic Review and Meta-analysis
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) 25, 1405 (2025); https://doi.org/10.2174/0118715206347612250314043307
/content/journals/acamc/10.2174/0118715206347612250314043307
/content/journals/acamc/10.2174/0118715206347612250314043307
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): B-cell lymphoma; chemoimmunotherapy; DLBCL; immunotherapy; Non-hodgkin lymphoma; pembrolizumab

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test